Sign In
Buy ADPT
$15.99
+0.85 (+5.61%)
At Close: Jun 03, 2026
Adaptive Biotechnologies Corporation (ADPT) Q3 2024 Earnings Call Transcript
09:57pm, Thursday, 07'th Nov 2024
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Karina Calzadilla - Head of IR Chad Robins - CEO and Co-Founder Ky
Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
07:30pm, Thursday, 07'th Nov 2024
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its
Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates
07:15pm, Thursday, 07'th Nov 2024
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.35 per share a year ago.
clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCL Coverage leverages new Medicare episode pricing established based on updated clonoSEQ gapfill rate SEATTLE,
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
04:05pm, Wednesday, 09'th Oct 2024
SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
07:30am, Thursday, 29'th Aug 2024
clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies clonoSEQ is the first IVDR-certified test to detect minimal residual disease in pati
Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
04:03pm, Thursday, 22'nd Aug 2024
SEATTLE, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
Adaptive Biotechnologies Corporation (ADPT) Q2 2024 Earnings Call Transcript
10:25pm, Thursday, 01'st Aug 2024
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Karina Calzadilla – Head-Investor Relations Chad Robins – Chief
Adaptive Biotechnologies (ADPT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
08:00pm, Thursday, 01'st Aug 2024
Although the revenue and EPS for Adaptive Biotechnologies (ADPT) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare w
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates
07:20pm, Thursday, 01'st Aug 2024
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.33 per share a year ago.
Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results
04:05pm, Thursday, 01'st Aug 2024
SEATTLE, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gen
3 Precision Medicine Stocks Tailoring Treatments
06:00am, Sunday, 21'st Jul 2024
Two elements favor the case for acquiring precision medicine stocks. First, the obvious point: barring extraordinary circumstances, the broader healthcare ecosystem will always be relevant.
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
04:05pm, Thursday, 11'th Jul 2024
SEATTLE, July 11, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers More than 20 abstracts will be presented
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
04:05pm, Wednesday, 29'th May 2024
SEATTLE, May 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syste
